South Korean pharmaceutical company Yuhan (KRX:000100) signed a contract to supply HIV treatment raw material pharmaceutical products (HIV API) to California-based Gilead Sciences.
The contract, valued till December 2026, is valued at 88.8 billion won, Yuhan said in a Thursday regulatory filing with Korea Exchange.
Shares of Yuhan fell nearly 2% in recent trade on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.